Caricamento...
A phase I study of TAS‐205 in patients with Duchenne muscular dystrophy
OBJECTIVE: Currently, the only approved standard Duchenne muscular dystrophy (DMD) treatment in Japan is oral steroids, which have various disadvantages. Previous work has suggested that hematopoietic‐type prostaglandin D synthase (HPGDS), involved in production of the inflammatory mediator prostagl...
Salvato in:
| Pubblicato in: | Ann Clin Transl Neurol |
|---|---|
| Autori principali: | , , , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
John Wiley and Sons Inc.
2018
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6243382/ https://ncbi.nlm.nih.gov/pubmed/30480028 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/acn3.651 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|